Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,597,582
  • Shares Outstanding, K 57,261
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,620 K
  • EBIT $ -142 M
  • EBITDA $ -148 M
  • 60-Month Beta -3.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.91

Options Overview Details

View History
  • Implied Volatility 86.63% ( +0.04%)
  • Historical Volatility 81.16%
  • IV Percentile 79%
  • IV Rank 17.09%
  • IV High 224.41% on 05/31/24
  • IV Low 58.22% on 08/23/24
  • Put/Call Vol Ratio 0.87
  • Today's Volume 6,938
  • Volume Avg (30-Day) 1,050
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 25,144
  • Open Int (30-Day) 23,853

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 6
  • High Estimate -0.19
  • Low Estimate -0.31
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.23 +6.37%
on 12/18/24
36.42 -23.40%
on 12/09/24
-4.81 (-14.70%)
since 11/20/24
3-Month
26.23 +6.37%
on 12/18/24
45.37 -38.51%
on 09/23/24
-14.02 (-33.44%)
since 09/20/24
52-Week
26.23 +6.37%
on 12/18/24
62.74 -55.53%
on 06/03/24
-5.09 (-15.43%)
since 12/20/23

Most Recent Stories

More News
Structure Therapeutics Inc. Advances ACCG-2671 as Lead Oral Amylin-Based Drug Candidate with Promising Preclinical Results

ACCG-2671 shows promise for weight loss and safety, with Phase 1 trials planned by late 2025.Quiver AI SummaryStructure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin...

GPCR : 27.90 (-6.91%)
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

GPCR : 27.90 (-6.91%)
2 ‘Monster’ Stocks to Snap Up Before 2025

Analysts at Jefferies have identified Metagenomi and Structure Therapeutics as two "monster" stocks in the biotech sector, with potential gains of up to 1,000%.

GPCR : 27.90 (-6.91%)
MGX : 4.05 (+4.92%)
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

GPCR : 27.90 (-6.91%)
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

GPCR : 27.90 (-6.91%)
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

GPCR : 27.90 (-6.91%)
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024 

GPCR : 27.90 (-6.91%)
Can Roche Challenge Lilly and Novo in the Weight Loss Market?

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

NVO : 85.00 (-17.83%)
LLY : 767.76 (+1.35%)
GPCR : 27.90 (-6.91%)
RHHBY : 34.5000 (+0.76%)
This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

NVO : 85.00 (-17.83%)
MS : 123.44 (+2.44%)
LLY : 767.76 (+1.35%)
GPCR : 27.90 (-6.91%)
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

NVO : 85.00 (-17.83%)
LLY : 767.76 (+1.35%)
GPCR : 27.90 (-6.91%)
SNY : 47.71 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 33.43
2nd Resistance Point 32.15
1st Resistance Point 30.03
Last Price 27.90
1st Support Level 26.63
2nd Support Level 25.35
3rd Support Level 23.23

See More

52-Week High 62.74
Fibonacci 61.8% 48.79
Fibonacci 50% 44.49
Fibonacci 38.2% 40.18
Last Price 27.90
52-Week Low 26.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar